Forte Biosciences downgraded by Truist with a new price target
$FBRX
Biotechnology: Pharmaceutical Preparations
Health Care
Truist downgraded Forte Biosciences from Buy to Hold and set a new price target of $4.00
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 4/8/2024 | $2.75 | Neutral → Buy | Ladenburg Thalmann |
| 9/20/2021 | $4.00 → $3.50 | Sell → Buy | Chardan Capital Markets |
| 9/20/2021 | $4.00 → $3.50 | Sell → Neutral | Chardan Capital |
| 9/3/2021 | Buy → Hold | Brookline Capital | |
| 9/3/2021 | Buy → Neutral | Ladenburg Thalmann | |
| 9/3/2021 | $105.00 → $4.00 | Buy → Sell | Chardan Capital Markets |
| 9/3/2021 | $4.00 | Buy → Hold | Truist |
| 9/3/2021 | $3.00 | Buy → Neutral | B. Riley Securities |
Brookline Capital analyst Kumaraguru Raja initiates coverage on Forte Biosciences (NASDAQ:FBRX) with a Buy rating and announces Price Target of $4.
Forte Biosciences (NASDAQ:FBRX) reported quarterly losses of $(0.32) per share which missed the analyst consensus estimate of $(0.17) by 88.24 percent.
Dr. Brun also appointed as Chairperson of Jasper Research and Development Committee and to Compensation Committee Board member Vishal Kapoor appointed to Jasper Audit and Compensation Committees REDWOOD CITY, Calif., June 20, 2023 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (NASDAQ:JSPR) (Jasper), a biotechnology company focused on the development of briquilimab, a novel antibody therapy targeting c-Kit (CD117) to address diseases such as chronic spontaneous urticaria (CSU), lower to intermediate risk myelodysplastic syndromes (LR-MDS) as well as novel stem cell transplant conditioning regimes, today announced the appointment of Scott Brun, M.D., to Jasper's Board of Directors. Dr. Bru
-FB-102 Continues to Advance Towards the Clinic and Holds Significant Market Potential Across a Variety of Indications- -Leadership Strengthened with the Appointment of Scott Brun, M.D. to the Board of Directors- -Ended third quarter 2022 with approximately $44.0 million in cash and cash equivalents- Forte Biosciences, Inc. (www.fortebiorx.com) (NASDAQ:FBRX), a biopharmaceutical company focused on autoimmune diseases, today announced third quarter 2022 results and provided a business update. "Forte is making excellent progress with its lead program FB-102, which is a direct result of the team's hard work and diligent efforts. FB-102 holds significant potential in a variety of indicatio
-Forte Leadership is Significantly Strengthened with the Appointment of Dr. Scott Brun, M.D. to the Board of Directors Forte Biosciences, Inc. (www.fortebiorx.com) (NASDAQ:FBRX), announced today that Dr. Scott Brun, M.D. has been appointed to the Forte Biosciences Board of Directors. Dr. Brun is currently a Venture Partner at Abingworth and in addition to his consulting practice, he is also a Senior Advisor for Horizon Therapeutics, and a Senior Medical Advisor at Launch Therapeutics. Dr. Brun previously served in numerous executive capacities at AbbVie, most recently as Head of AbbVie Ventures. In Dr. Brun's previous role as Head of Product Development at Abbvie, he led the global organi
Ladenburg Thalmann upgraded Forte Biosciences from Neutral to Buy and set a new price target of $2.75
Chardan Capital Markets upgraded Forte Biosciences from Sell to Buy and set a new price target of $3.50 from $4.00 previously
Chardan Capital upgraded Forte Biosciences from Sell to Neutral and set a new price target of $3.50 from $4.00 previously
SC 13G/A - Forte Biosciences, Inc. (0001419041) (Subject)
SC 13G/A - Forte Biosciences, Inc. (0001419041) (Subject)
SC 13D/A - Forte Biosciences, Inc. (0001419041) (Subject)
Forte Biosciences, Inc. (www.fortebiorx.com) (NASDAQ:FBRX), a clinical-stage biopharmaceutical company focused on autoimmune and autoimmune-related diseases, today announced it will host an R&D Day on December 3, 2024 at 4:30 p.m. ET. The R&D Day will focus on the development of FB102 across autoimmune indications and will feature key thought leaders in celiac disease, vitiligo and alopecia areata including Prof. Jason Tye-Din MD, PhD, Head of Celiac Research at the Walter and Eliza Hall Institute, Prof. Christopher Ma MD, MPH, FRCPC, academic gastroenterologist at the Cumming School of Medicine, University of Calgary and Prof. David Rosmarin, MD, Chair of the Department of Dermatology at
Forte Biosciences, Inc. (www.fortebiorx.com) (NASDAQ:FBRX), a clinical-stage biopharmaceutical company focused on autoimmune and autoimmune-related diseases, today announced an oversubscribed $53 million equity financing to support the continuing clinical advancement of FB102. "We are appreciative of the support from new and existing investors including OrbiMed, Janus Henderson Investors, Tybourne Capital Management, Alger, Ikarian Capital, LLC, BVF Partners LP, and The Red Hook Fund LP. This financing by high quality institutional investors is transformative for Forte and highlights the meaningful potential for FB102. As a result of the financing, Forte is well capitalized to continue ad
Forte Biosciences, Inc. (www.fortebiorx.com) (NASDAQ:FBRX), a clinical-stage biopharmaceutical company focused on autoimmune and autoimmune-related diseases, today announced third quarter 2024 results and provided a business update. Third Quarter 2024 Business Highlights "We continue to make excellent progress with FB102 and have begun dosing patients in a celiac disease clinical trial. In addition to safety and tolerability, we will be assessing the histological impact as well as a variety of other activity parameters. The topline data is expected to readout in the second quarter of 2025," said Paul Wagner, Ph.D., Chairman and Chief Executive Officer of Forte Biosciences. "Based on the
4 - Forte Biosciences, Inc. (0001419041) (Issuer)
4 - Forte Biosciences, Inc. (0001419041) (Issuer)
4 - Forte Biosciences, Inc. (0001419041) (Issuer)
Forte Biosciences, Inc. (www.fortebiorx.com) (NASDAQ:FBRX), a clinical-stage biopharmaceutical company, today announced that topline data from its Phase 2 clinical trial of FB-401 for the treatment of atopic dermatitis failed to meet statistical significance for the primary endpoint of EASI-50 (the proportion of patients with at least a 50% improvement in atopic dermatitis disease severity as measure by EASI). Positive trends were observed in key secondary endpoints including EASI-90 with 27.6% of subjects in the active arm achieving the EASI-90 endpoint compared to 20.5% in the control arm (p=0.3075) and in IGA success (2 point reduction and clear or almost clear) with 38.2% of active sub
Forte Biosciences, Inc. (www.fortebiorx.com) (NASDAQ:FBRX), a clinical-stage biopharmaceutical company, will review the second quarter results and, based on the projected timing of database lock and completion of statistical programming and analysis, expects to announce topline data from its Phase 2 clinical trial of FB-401 for the treatment of atopic dermatitis on September 7, 2021. Conference Call and Webcast Information Forte management will host a conference call and webcast on Tuesday, September 7th at 8.00 AM Eastern Time. Participants may access the call by dialing 877-705-6003 (Domestic) or 201-493-6725 (International). The conference ID number is: 13722132. Participants may also
8-K - Forte Biosciences, Inc. (0001419041) (Filer)
10-Q - Forte Biosciences, Inc. (0001419041) (Filer)
8-K - Forte Biosciences, Inc. (0001419041) (Filer)
4 - Forte Biosciences, Inc. (0001419041) (Issuer)
4 - Forte Biosciences, Inc. (0001419041) (Issuer)
4 - Forte Biosciences, Inc. (0001419041) (Issuer)